Protocol Ledger

NCT06855771 · Phase II · RECRUITING

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP

Interventional Phase II clinical trial protocol NCT06855771 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-09 Enrollment: 182 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06855771
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)182 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06855771
Protocol FieldVerified Registry Value
NCT IdentifierNCT06855771
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment182 participants (ESTIMATED)
Registered Start Date2025-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI